摘要
Doxorubicin-Induced Oxidative Injury of Cardiomyocytes -Do We Have Right Strategies for Prevention? 91that myocyte damage and ventricular dysfunction progress after the initial myocardial insult and may lead to late-onset cardiac decompensation.Although the DOX dose of 550 mg/m 2 was suggested to be relatively safe, CHF was found to begin at a lower cumulative dose in the presence of other risk factors, such as age above 70 years, combination therapy (cyclophosphamide, dacarbazine etc.), previous or concomitant mediastinal radiotherapy, history of pre-existing cardiac disease, or liver disease (Ludke et al., 2009;Singal & Iliskovic, 1998;Sweetman, 2011).Although sensitivity to DOX-induced cardiotoxicity exhibit large interindividual variation, the risk of developing impairment in myocardial function increases with increasing cumulative dose, occurring in 3-5, 5-8, and 6-20% in those receiving cumulative doses of 400, 450, or 500 mg/m 2 , respectively, in schedules of rapid IV doses given every 3 weeks.The strong association between cumulative DOX dose and cardiotoxicity obviously is more important with increasing time after treatment (Lipshultz & Adams, 2010).Some clinicians suggest that late-onset cardiotoxicity can be clinically manifest in response to stressful situations (e.g.surgery, pregnancy), exercise and viral infection.Late-onset doxorubicin toxicity can be expected to be observed more frequently with the growing number of long-time survivors (survivors of childhood cancers) who have received DOX.Long term follow up shows that overt cardiac failure occurs from 0 to 16% of patients receiving anthracycline therapy.It depends on the cumulative dose, well recognized risk factor for late cardiotoxicity, radiation therapy involving the heart, age at diagnosis, greater length of follow up, higher dose rate and previous exposure to anthracycline (Kremer et al., 2002;McEvoy et al., 2010;Wouters et al., 2005).Therefore, recommendations for screening and management of late effects of therapeutic exposure used during treatment for pediatric malignancies are very important in every day practice. Monitoring and markers of doxorubicin-induced cardiotoxicityClinical manifestations found on physical examination, and/or changes found on electrocardiographic (ECG) monitoring are not specific enough to diagnose DOX-induced cardiotoxicity.However, a persistent reduction in the voltage of the QRS wave is generally indicative of the need to perform further tests.Non-invasive cardiac monitoring, by means of serial echocardiography studies or radionuclide angiography, is useful in predicting the development of cardiomyopathy.However, since it may give normal results until damage is quite advanced, sensitivity may be improved with exercise stress tests (Singal & Iliskovic, 1998;Steinherz et al., 1992).Endomyocardial biopsy is the most sensitive indicator of cardiomyopathy, but it is limited by its invasiveness, need for histologic expertise, and costs.Therefore, there is need for simple methods, like serum and plasma markers to identify patients at risk.There is some preliminary evidence to suggest that concentrations of cardiac troponins and natriuretic peptides could be used as predictive markers of myocardial damage (Ludke et al., 2009;Schimmel et al., 2004).Anyway, according to the Childrens' Cancer Study Group (Steinherz et al., 1992), standard echocardiogram should be performed before the beginning of the treatment and at the third, sixth and 12 th month after its completion.Subsequent exam should be repeated every 2 years for the rest of the life. Prognosis and treatmentHistorically, DOX-induced cardiomyopathies have a poor prognosis and mortality rate as high as 61% (Allen, 1992;Von Hoff et al., 1979;Wouters et al., 2005).It is refractory to www.intechopen.